About Savvyn
Savvyn helps healthcare product teams build the proof needed to win insurance coverage and reach patients. Its software gathers research for medical affairs, market access and startup teams working on diagnostics, devices and treatments. It compares that material with payer and assessment requirements, finds evidence gaps and helps draft submissions. Each claim links to its source, while the system reruns its analysis when publications, coverage rules or competitor information changes.
Based in Cumberland, Maine, Savvyn is led by co-founders Catherine Del Vecchio Fitz, chief executive officer, and Caroline Webster, chief technology officer. Its wider team covers operations, data and software infrastructure.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | Nov 10, 2026 | $50,000of $100K target | 1 | $50,000 | Simple Agreement for Future Equity (SAFE)Rule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Savvyn
Savvyn sells evidence software to healthcare product teams. It targets the gap between strong science and payer coverage. Savvyn argues that specialized AI can pair speed with consulting expertise and an audit trail. In its pitch, earlier coverage brings revenue forward, reduces manual work and lowers fundraising risk.
The problem it targets
Medical affairs and market access teams must assemble studies, policy rules and earlier decisions for products seeking coverage. Teams preparing U.S. payer and European health technology assessment submissions need to understand what was required before. Reviewers may ask whether a product performs technically, works in patients and changes care in a useful way. New research, policy updates and competitor moves can make a static dossier outdated. Savvyn presents this changing set of requirements as a source of delay and repeated manual work.
What the product does
The system structures every source and traces each number to its original sentence. It maps intended uses against guidelines, past regulatory milestones and competitor products. It then checks the evidence against each review area and marks gaps by severity. Users can inspect coverage by indication, ask questions with line-level citations and review dossier updates triggered by new evidence. Client data is never used to train AI models.
Progress so far
Validation covered 673 corpus elements. The measured results were 99.4% citation traceability and a 0.8% hallucination rate. In March 2026, Savvyn joined Dirigo Labs’ 12-startup accelerator cohort. It placed second in the Maine Startup Challenge in May, earning $2,000. Later that year, it presented at BioMaine’s Startup Showcase and became a finalist for the Maine Community Bank Emerging Business Award. The company also took part in a healthcare-data panel during Startup Maine Week.
Who backs it
Support has come through accelerators, grant programs and in-kind work. A Maine Technology Institute feasibility grant supported validation of the product’s evidence corpus. Savvyn also lists the Maine Startup Accelerator, Central Maine Growth Council and Google for Startups Cloud Program among its programs and supporters. Colby College students contributed in-kind work on biomedical AI and data systems.
We wrote this summary from public statements by Savvyn and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Savvyn's Form D filed Nov 10, 2026.
Sources
- SECSavvyn, PBC filing history
- CompanyWho We Are | Savvyn
- CompanyPrivacy | Savvyn